Raising Awareness for Men’s Health and Prostate Cancer
Whether you want to grow a mustache or sport one for fun, join Onco360 as we help support Movember for prostate cancer awareness in November. We have access to a large portfolio of prostate cancer medications such as Abiraterone and LDD drugs, plus we provide ongoing and personalized support including medication adherence, side effect management, and expert funding assistance by our OncoAdvocate Team®.
We secured over $132 million in funding assistance for our prostate cancer patients in 2023, including those on medications such as Abiraterone
Currently, our prostate cancer patients’ average copay is $24
97% of our prostate cancer patients paid less than $50 for their last dispense
We are Unmatched in Prostate Cancer Pharmacy Care
- Innovative and personalized Prostate Medication Therapy Management Program for eligible patients
- Best-in-class patient satisfaction, with an NPS score of 94*
- Quick turnaround for Commercial and Medicare benefit verification and prior authorizations
- Our real-time Provider Portal, Onco360 Compass, provides complete visibility into the patient journey
Onco360 dispenses these prostate cancer and urology medications
**This list is a small portion of the comprehensive medications Onco360 can provide
Casodex® (bicalutamide)
Erleada® (apalutamide)
Firmagon® (degarelix)
Jevtana® (cabazitaxel)
Keytruda® (pembrolizumab)
Lupron® (leuprolide)
Orgovyx® (relugolix)
Taxotere® (doxetaxel)
Trelstar® (triptorelin)
Xtandi® (enzalutamide)
Yonsa® (abiraterone acetate, micronized)
Zytiga® (abiraterone acetate)
*Third-party survey data provided by MMIT for Q4 2023. MMITnetwork.com